Hemispherx (NYSE American:HEB) has announced the active initiation of a clinical trial sponsored by Roswell Park Comprehensive Cancer Center, evaluating the company’s experimental drug Ampligen in combination with Merck’s (NYSE:MRK) Keytruda in treating metastatic triple-negative breast cancer. As quoted in the press release: The study’s first participant received initial dosing this week. The phase I … Continued
The post Hemispherx Announces First Participant Received Initial Dosing in Breast Cancer Clinical Trial appeared first on Investing News Network.